South San Francisco, California, USA | March 22, 2026
IDEAYA Biosciences has announced updated guidance on the anticipated topline data release from its Phase 2/3 OptimUM-02 clinical trial, evaluating darovasertib-based therapy in first-line metastatic uveal melanoma, alongside participation in upcoming investor and analyst events. The company confirmed that database lock is expected in early April 2026, followed by topline data analysis shortly thereafter, marking a critical milestone in the development of this precision oncology therapy targeting a rare and aggressive cancer.
Phase 2/3 Trial Progress Signals Key Clinical Milestone
The OptimUM-02 trial is a registrational Phase 2/3 study designed to evaluate darovasertib in combination therapy for patients with HLA-A2-negative metastatic uveal melanoma, a rare cancer with limited treatment options and poor prognosis. The updated timeline indicates that topline results are imminent, positioning the study at a pivotal stage in clinical development with potential implications for regulatory submission and future approval pathways.
The trial is expected to generate critical data on efficacy endpoints such as progression-free survival (PFS) and overall clinical benefit, which will determine the therapy’s potential as a first-line treatment option. Given the lack of effective therapies in this indication, the results could represent a significant advancement in targeted oncology and precision medicine approaches.
Darovasertib Targets Molecular Drivers of Cancer
Advertisement
Darovasertib is a selective protein kinase C (PKC) inhibitor, designed to target key signaling pathways involved in tumor growth and survival in uveal melanoma. IDEAYA’s approach integrates translational biomarkers and molecular profiling, enabling the development of tailored therapies aligned with genetic drivers of disease, a cornerstone of modern precision oncology.
The drug is part of IDEAYA’s broader pipeline focused on synthetic lethality and targeted therapeutics, aiming to deliver first-in-class treatments for genetically defined cancers. The ongoing trial reflects the company’s strategy of combining small-molecule innovation with biomarker-driven patient selection, enhancing the likelihood of clinical success and regulatory approval.
Regulatory and Commercial Implications Ahead
The upcoming topline data release represents a critical inflection point for IDEAYA, as positive results could support regulatory engagement and potential new drug application (NDA) filings. The company plans to host a live investor and analyst webcast following data availability, providing detailed insights into the trial outcomes and next steps in development.
In parallel, IDEAYA will participate in major industry events, including the Bank of America Merrill Lynch Health Care Conference and the Stifel Targeted Oncology Virtual Forum, reflecting growing interest in its oncology pipeline and clinical progress.
From a cGxP perspective, the OptimUM-02 trial underscores the importance of robust clinical trial execution, data integrity, and regulatory readiness, as the study approaches database lock and data analysis stages, which are critical for submission-quality datasets and compliance with Good Clinical Practice (GCP) standards.
The updated timeline for the OptimUM-02 trial positions darovasertib at a late-stage clinical development milestone, with topline data expected imminently. As a targeted therapy addressing a high unmet medical need in metastatic uveal melanoma, darovasertib has the potential to transform treatment paradigms and improve patient outcomes. The upcoming results will be closely watched by the global oncology and regulatory community, as they may define the next steps toward approval and commercialization in precision oncology.
Source: IDEAYA Biosciences press release
